Papulopustular Rosacea is a chronic skin disease that affects 16 million Americans and 34 million people globally. It causes redness and inflammatory lesions or patches on the face. The patients suffer from itching, stinging, and embarrassment. They become self-conscious and avoid leisure and social activities. This study evaluated the role of Minocycline topical gel in clearing up the lesions.

The objective was to assess the safety and efficacy of Minocycline 1% and 3% when used once every day. Researchers conducted a double-blind study at 26 sites in the USA for over 12 weeks with participants included 270 rosacea patients, with 12 to 40 inflammatory lesions. Researchers created three randomized groups for Minocycline 1%, 3%, and the vehicle (placebo). The mean change in swelling after 12 weeks was the primary endpoint. Investigator’s Global Assessment (IGA) gauged the success of secondary key points.

The baseline lesion count in three groups was 24.6, 25.1, and 24.3. At the primary endpoint, the lesions decreased by 12.6, 13.1, and 7.9. When compared to the vehicle, the gel groups did exceedingly well. They had 95% confidence with P values of 0.01 and 0.007 for 1% and 3% groups. The IGA success in these groups was also 39% and 46%, respectively. In comparison, the vehicle group only had IGA success of 31%.

The Minocycline topical gel is safe and tolerable in treating Rosacea lesions. At week 12, the 3% group had more IGA success in swelling reduction than the 1% gel users.